Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Drosophila model to clarify the pathological significance of OPA1 in autosomal dominant optic atrophy

View through CrossRef
Abstract Autosomal dominant optic atrophy (DOA) is a progressive form of blindness caused by degeneration of retinal ganglion cells and their axons, mainly caused by mutations in the OPA1 mitochondrial dynamin like GTPase (OPA1) gene. OPA1 encodes a dynamin-like GTPase present in the mitochondrial inner membrane. When associated with OPA1 mutations, DOA can present not only ocular symptoms but also multi-organ symptoms (DOA plus). DOA plus often results from point mutations in the GTPase domain, which are assumed to have dominant negative effects. However, the presence of mutations in the GTPase domain does not always result in DOA plus. Therefore, an experimental system to distinguish between DOA and DOA plus is needed. In this study, we found that loss-of-function mutations of the dOPA1 gene in Drosophila can imitate the pathology of optic nerve degeneration observed in DOA. We successfully rescued this degeneration by expressing the human OPA1 (hOPA1) gene, indicating that hOPA1 is functionally interchangeable with dOPA1 in the fly system. However, we could not rescue any previously reported mutations known to cause either DOA or DOA plus. By expressing both WT and DOA plus mutant hOPA1 forms in the optic nerve of dOPA1 mutants, we observed that DOA plus mutations suppressed the rescue, facilitating the distinction between loss-of-function and dominant negative mutations in hOPA1. The fly model developed in this study can assist in the differential diagnosis between DOA and DOA plus and inform early treatment decisions in patients with mutations in hOPA1.
Title: Drosophila model to clarify the pathological significance of OPA1 in autosomal dominant optic atrophy
Description:
Abstract Autosomal dominant optic atrophy (DOA) is a progressive form of blindness caused by degeneration of retinal ganglion cells and their axons, mainly caused by mutations in the OPA1 mitochondrial dynamin like GTPase (OPA1) gene.
OPA1 encodes a dynamin-like GTPase present in the mitochondrial inner membrane.
When associated with OPA1 mutations, DOA can present not only ocular symptoms but also multi-organ symptoms (DOA plus).
DOA plus often results from point mutations in the GTPase domain, which are assumed to have dominant negative effects.
However, the presence of mutations in the GTPase domain does not always result in DOA plus.
Therefore, an experimental system to distinguish between DOA and DOA plus is needed.
In this study, we found that loss-of-function mutations of the dOPA1 gene in Drosophila can imitate the pathology of optic nerve degeneration observed in DOA.
We successfully rescued this degeneration by expressing the human OPA1 (hOPA1) gene, indicating that hOPA1 is functionally interchangeable with dOPA1 in the fly system.
However, we could not rescue any previously reported mutations known to cause either DOA or DOA plus.
By expressing both WT and DOA plus mutant hOPA1 forms in the optic nerve of dOPA1 mutants, we observed that DOA plus mutations suppressed the rescue, facilitating the distinction between loss-of-function and dominant negative mutations in hOPA1.
The fly model developed in this study can assist in the differential diagnosis between DOA and DOA plus and inform early treatment decisions in patients with mutations in hOPA1.

Related Results

Drosophila model to clarify the pathological significance of OPA1 in autosomal dominant optic atrophy
Drosophila model to clarify the pathological significance of OPA1 in autosomal dominant optic atrophy
Abstract Autosomal dominant optic atrophy (DOA) is a progressive form of blindness caused by degeneration of retinal ganglion cells and their axons, mainly caused by mutations in t...
OPA 1 and Its Clinical Implications
OPA 1 and Its Clinical Implications
Abstract Autosomal dominant optic atrophy (ADOA) or Kjer disease (MIM # 165500 ) is a primary inherit...
Clinical features of COVID-19-related optic neuritis: a retrospective study
Clinical features of COVID-19-related optic neuritis: a retrospective study
ObjectiveThis retrospective study aimed to investigate the clinical features of optic neuritis associated with COVID-19 (COVID-19 ON), comparing them with neuromyelitis optica-asso...
ATF4-dependent and independent mitokine secretion from OPA1 deficient skeletal muscle in mice is sexually dimorphic
ATF4-dependent and independent mitokine secretion from OPA1 deficient skeletal muscle in mice is sexually dimorphic
IntroductionReducing Optic Atrophy 1 (OPA1) expression in skeletal muscle in male mice induces Activation Transcription Factor 4 (ATF4) and the integrated stress response (ISR). Ad...
Optic Neuropathy after COVID-19 Vaccination: Case Report and Systematic Review
Optic Neuropathy after COVID-19 Vaccination: Case Report and Systematic Review
Abstract Purpose: To report a case of anterior ischemic optic neuropathy (AION) following COVID-19 vaccination and provide a systematic review of all published cases of op...
Poster 247: Muscle ERRγ Overexpression Mitigates the Muscle Atrophy after ACL injury
Poster 247: Muscle ERRγ Overexpression Mitigates the Muscle Atrophy after ACL injury
Objectives: Anterior cruciate ligament (ACL) reconstruction is the 6th most common orthopedic procedure performed in the United States (1,2). There is substantial evidence to sugge...
1642-P: Deferoxamine Prevented Dexamethasone-Induced Muscle Atrophy through Inhibition of KLF15 and FOXO3a
1642-P: Deferoxamine Prevented Dexamethasone-Induced Muscle Atrophy through Inhibition of KLF15 and FOXO3a
Aim/hypothesis: Muscle atrophy is caused by various factors such as aging, a lack of exercise, and diseases. During these events, the balance between protein synthesis and degradat...

Back to Top